532 related articles for article (PubMed ID: 172562)
1. Humoral and cellular immune responses to an envelope-associated antigen of herpes simplex virus.
Zaia JA; Palmer EL; Feorino PM
J Infect Dis; 1975 Dec; 132(6):660-6. PubMed ID: 172562
[TBL] [Abstract][Full Text] [Related]
2. Immunogenic properties of formalin herpes antigen prepared from cell cultures.
Benda R; Dbalý V
J Hyg Epidemiol Microbiol Immunol; 1973; 17(2):237-49. PubMed ID: 4354219
[No Abstract] [Full Text] [Related]
3. Comparison of the humoral and cellular immune response after immunization with live, UV inactivated herpes simplex virus and a subunit vaccine and efficacy of these immunizations.
Cappel R
Arch Virol; 1976; 52(1-2):29-35. PubMed ID: 187150
[TBL] [Abstract][Full Text] [Related]
4. Stimulation of peripheral blood lymphocytes by herpes simplex virus in vitro.
Scriba M
Infect Immun; 1974 Sep; 10(3):430-6. PubMed ID: 4372170
[TBL] [Abstract][Full Text] [Related]
5. Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir.
Hensel MT; Marshall JD; Dorwart MR; Heeke DS; Rao E; Tummala P; Yu L; Cohen GH; Eisenberg RJ; Sloan DD
J Virol; 2017 May; 91(9):. PubMed ID: 28228587
[TBL] [Abstract][Full Text] [Related]
6. Regulation of expression of herpes simplex virus (HSV) glycoprotein D in vaccinia recombinants affects their ability to protect from cutaneous HSV-2 disease.
Wachsman M; Aurelian L; Smith CC; Perkus ME; Paoletti E
J Infect Dis; 1989 Apr; 159(4):625-34. PubMed ID: 2538519
[TBL] [Abstract][Full Text] [Related]
7. Immunization of experimental animals with reconstituted glycoprotein mixtures of herpes simplex virus 1 and 2: protection against challenge with virulent virus.
Meignier B; Jourdier TM; Norrild B; Pereira L; Roizman B
J Infect Dis; 1987 May; 155(5):921-30. PubMed ID: 3031174
[TBL] [Abstract][Full Text] [Related]
8. Immune responses to herpes simplex virus in guinea pigs (footpad model) and mice immunized with vaccinia virus recombinants containing herpes simplex virus glycoprotein D.
Aurelian L; Smith CC; Wachsman M; Paoletti E
Rev Infect Dis; 1991; 13 Suppl 11():S924-34. PubMed ID: 1664130
[TBL] [Abstract][Full Text] [Related]
9. Recombinant interleukin 2 as an adjuvant for vaccine-induced protection. Immunization of guinea pigs with herpes simplex virus subunit vaccines.
Weinberg A; Merigan TC
J Immunol; 1988 Jan; 140(1):294-9. PubMed ID: 2826591
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of a nucleic acid free herpetic subunit vaccine.
Cappel R; de Cuyper F; Rickaert F
Arch Virol; 1980; 65(1):15-23. PubMed ID: 6252864
[TBL] [Abstract][Full Text] [Related]
11. Induction of cellular immunity to herpes simplex virus: relationship to the humoral immune response.
Rosenberg GL; Notkins AL
J Immunol; 1974 Mar; 112(3):1019-25. PubMed ID: 4359780
[No Abstract] [Full Text] [Related]
12. Immunogenicity of subviral herpes simplex virus preparations: protection of mice against intraperitoneal infection with live virus.
Kutinová L; Vonka V; Slichtová V
Acta Virol; 1980 Dec; 24(6):391-8. PubMed ID: 6111199
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity of subviral herpes simplex virus preparations. I. Formation of neutralizing antibodies in different animal species after administration of herpes simplex virus solubilized antigens.
Kutinová L; Slichtová V; Vonka V
Arch Virol; 1979; 61(1-2):141-7. PubMed ID: 229789
[TBL] [Abstract][Full Text] [Related]
14. Native herpes simplex virus glycoprotein D vaccine: immunogenicity and protection in animal models.
Mishkin EM; Fahey JR; Kino Y; Klein RJ; Abramovitz AS; Mento SJ
Vaccine; 1991 Mar; 9(3):147-53. PubMed ID: 1645898
[TBL] [Abstract][Full Text] [Related]
15. Nonvirion antigens produced by herpes simplex viruses 1 and 2.
Tarro G; Sabin AB
Proc Natl Acad Sci U S A; 1973 Apr; 70(4):1032-6. PubMed ID: 4352219
[TBL] [Abstract][Full Text] [Related]
16. Induction and enhancement of immune responses to herpes simplex virus type 2 in humans by use of a recombinant glycoprotein D vaccine.
Straus SE; Savarese B; Tigges M; Freifeld AG; Krause PR; Margolis DM; Meier JL; Paar DP; Adair SF; Dina D
J Infect Dis; 1993 May; 167(5):1045-52. PubMed ID: 8387560
[TBL] [Abstract][Full Text] [Related]
17. Yeast-derived glycoprotein B-1 of herpes simplex virus (HSV) as a candidate for an HSV vaccine.
Kino Y
Adv Exp Med Biol; 1990; 278():183-90. PubMed ID: 1963033
[No Abstract] [Full Text] [Related]
18. In vitro stimulation of sensitized lymphocytes by herpes simplex virus and vaccinia virus.
Rosenberg GL; Farber PA; Notkins AL
Proc Natl Acad Sci U S A; 1972 Mar; 69(3):756-60. PubMed ID: 4335071
[TBL] [Abstract][Full Text] [Related]
19. Protection from oral herpes simplex virus infection by a nucleic acid-free virus vaccine.
Kitces EN; Morahan PS; Tew JG; Murray BK
Infect Immun; 1977 Jun; 16(3):955-60. PubMed ID: 197013
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of a virion envelope herpes simplex virus vaccine against experimental skin infections in hairless mice.
Klein RJ; Buimovici-Klein E; Moser H; Moucha R; Hilfenhaus J
Arch Virol; 1981; 68(2):73-80. PubMed ID: 6264897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
